Navigation Links
Lupin Limited: Quarter III Results, FY 2012-13
Date:1/31/2013

MUMBAI, January 31, 2013 /PRNewswire/ --

Record Sales and Profits

Net Sales up 38%, EBITDA up 68%, PAT up 43%

BSE: 500257 | NSE: LUPIN | REUTERS: LUPIN.BO | BLOOMBERG: LPC IN

Pharma Major, Lupin Ltd. reported its performance for the third quarter ended 31st December, 2012. These unaudited results were taken on record by the Board of Directors at a meeting in Mumbai today.

  • Net sales grew by 37.6% to Rs. 24,659 m. during Q3 FY 2012-13, up from Rs. 17,917 m. (Q3 FY 2011-12)
    • 9M FY 2012-13: YoY growth of 36.4% to Rs. 69,243 m. from Rs. 50,765 m.
  • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) grew by 67.6% to Rs. 6,314 m. during Q3 FY 2012-13, up from Rs. 3,768 m. (Q3 FY 2011-12)
    • 9M FY 2012-13: YoY growth of 51.5% to Rs. 16,329 m. from Rs. 10,781 m.
  • Profit before tax (PBT) grew by 78.6% to Rs. 5,550 m. during Q3 FY 2012-13, up from Rs. 3,107 m. (Q3 FY 2011-12)
    • 9M FY 2012-13: YoY growth of 55.8% to Rs. 14,020 m. from Rs. 9,001 m.
  • Net profits grew by 42.6% to Rs. 3,352 m. during Q3 FY 2012-13, up from Rs. 2,351 m. (Q3 FY 2011-12)
    • 9M FY 2012-13: YoY growth of 27.3% to Rs. 9,061 m. from Rs. 7,120 m.

Commenting on the results, Dr. Kamal K. Sharma , Managing Director, Lupin Limited, said "We had a record quarter driven by strong operating performance and growth in the US. Importantly, we continue to improve on margins consistently."

Unaudited consolidated financial results for the quarter ended December 31st, 2012 (YoY comparison)

Figures in Rs. m

% of net % of net YoY Particulars Q3 2012-13 sales Q3 2011-12 sales growth % Net sales 24,659 100% 17,917 100.0% 37.6% Other operating income 352 1.4% 286 1.6% 23.2% Total revenue 25,011 101.4% 18,203 101.6% 37.4% Raw material consumed 9,357 37.9% 6,258 34.9% 49.5% Gross margin (excl. other operating income) 15,302 62.1% 11,659 65.1% 31.2% Employees cost 3,165 12.8% 2,524 14.1% 25.4% Manufacturing & other expenses 6,440 26.1% 5,673 31.7% 13.5% Operating margin 6,049 24.5% 3,748 20.9% 61.4% Other income 265 1.1% 20 0.1% 1245.8% EBITDA 6,314 25.6% 3,768 21.0% 67.6% Depreciation 688 2.8% 576 3.2% 19.4% EBIT 5,626 22.8% 3,192 17.8% 76.3% Interest & finance charges 76 0.3% 85 0.5% -10.4% PBT 5,550 22.5% 3,107 17.3% 78.6% Tax 2,116 8.6% 701 3.9% 201.8% PAT 3,434 13.9% 2,406 13.4% 42.7% Minority interest & share of loss in associates 82 0.3% 55 0.3% 48.4% Net profit 3,352 13.6% 2,351 13.1% 42.6%

Balance sheet highlights

  • Operating working capital increased to Rs. 22,855 m. as on 31st December, 2012 as against Rs. 21,322 m. as on 30th September, 2012.  The working capital number of days stands at 90 days as on 31st December, 2012 as against 87 days on 30th September, 2012.
  • Capital Expenditure stood at Rs. 970 m. during the quarter.
  • Debt Equity Ratio as on 31st December, 2012, was 0.21.

YOY growth Particulars Q3 2012-13 Q3 2011-12 % Formulations 22,306 15,936 40% US (including IP) 10,390 6,188 68% Europe 598 644 -7% India 5,708 5,011 14% Japan 3,658 2,468 48% South Africa 831 583 43% Rest of world 1,121 1,042 8% API 2,353 1,981 19% Total net sales 24,659 17,917 38%

US & Europe

US & Europe formulation sales contributed 44% to the Company's overall consolidated revenues for Q3 FY 2012-13. Formulation Sales for US & Europe grew by 60% to Rs. 10,829 m. during Q3 FY 2012-13, as against Rs. 6,763 m. Q3 FY 2011-12. Lupin is now the market leader in 22 products out of the 43 products it markets in the US generics market. The Company is amongst the Top 3 by market share in 38 of these products.

India formulations

The Indian formulations contributed 23% of the Company's overall revenues for the quarter. The Company's India formulations business grew by 14% recording net revenues of Rs. 5,708 m. during Q3 FY 2012-13, as compared to Rs. 5,011 m. in Q3 FY 2011-12.

Japan

Lupin's Japan Sales (Kyowa + I'rom) grew by 48% clocking net sales of Rs. 3,658 m. during the quarter, as compared to Rs. 2,468 m. in Q3 FY 2011-12. Japan now contributes 15% to Lupin's consolidated revenues. Total revenues increased to JPY 5,497 m. from JPY 3,855 m., a growth of 43% in JPY terms.

R&D

Revenue expenditure on R&D for Q3 FY 2012-13 amounted to Rs. 2,382 m., 9.7% to net sales as against Rs. 1,410 m., 7.9% to net sales in Q3 FY 2011-12.

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

For the financial year ended March 2012, Lupin's Consolidated Total Income and Profit after Tax were Rs. 70,972 million (USD 1.49 billion) and Rs. 8,676 million (USD 182 million) respectively. Please visit http://www.lupinworld.com for more information.

For further information or queries please contact -

Shamsher Gorawara
Head - Corporate Communications
Lupin Limited:
Ph: +91-98-20-338-555
Email: shamshergorawara@lupinpharma.com


'/>"/>
SOURCE Lupin Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Building on a Legacy: Vinita Gupta, CEO of Lupin Pharmaceuticals, Inc., Named Ernst & Young U.S. 2012 Family Business Award of Excellence winner
2. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
3. Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013
4. TPI to Host Second Quarter of Fiscal Year 2013 Earnings Conference Call on Thursday, February 14, 2013 at 8:30 a.m. ET
5. Zimmer Reports Fourth Quarter and 2012 Financial Results
6. VirtualScopics Schedules Fourth Quarter and Full Year 2012 Earnings Announcement
7. Masimo to Report Fourth Quarter and Full Year 2012 Financial Results after Market Close on Thursday, February 14
8. The Female Health Company Reports Record First Quarter FY2013 Operating Results
9. Avanir Pharmaceuticals Announces Date Of Fiscal 2013 First Quarter Financial Results And Conference Call
10. Genomic Health to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday, February 6, 2013
11. PDL BioPharma Announces 2013 Regular Quarterly Dividends
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):